Alliance for Cancer Gene Therapy’s Post

🔎 ZOOM ON... GvHD models #GvHD is a significant complication of allogeneic transplants, characterized by an immune-mediated attack on the recipient's tissues by donor cells. At Oncodesign Services, we have developed GvHD models to: - understand the pathophysiology of GvHD, - test potential therapeutic interventions and - optimize treatment strategies, using a combination of in vitro and in vivo platforms. For more information, click here 👇 https://ow.ly/xoek50SjQrQ

Hello guys, check out my first author original article in Scientific Reports! 💪 Highlights of the paper! -We have very nicely described a novel subtype of hepatic stellate cells ( zone 1-HSC) -This subtype of HSC resides in Zone 1 of the liver lobule under healthy conditions and loses zonation during fibrosis -Importantly, zone 1-HSC do not transform into αSMA-expressing myofibroblasts -Rather, they participate in sinusoidal capillarization in preclinical models of liver fibrosis

🔬Citation Break!📖 This citation investigates the potential role of IGF-1 in Alzheimer's Disease and how it may contribute to neuroinflammation. Our Beta-Amyloid (1-42) NaOH (Cat# A-1165) was used in MTT assays with microglia cells, in Phagocytosis Assays, and ELISAs. We also offer FITC-conjugated BA 1-42 for those wishing to explore similar experiments using a fluorescent molecule. Paper: https://t.ly/9PjP8 Beta-Amyloid (1-42) NaOH: https://t.ly/wwyyQ #Research #Development #rPeptide #Experiments #BetaAmyloid #NaOH

#PaperoftheDay: "Melatonin downregulates angiogenesis and lymphangiogenesis by regulating tumor-associated macrophages via NLRP3 inflammasomes in lung adenocarcinoma" DOI ⬇️ https://lnkd.in/e8XPvFTk #melatonin #aging #research #openaccess #peerreview #publishing

Brain metastases represent the most common intracranial tumors in adults and are associated with a poor prognosis. Read our newest publication on identifying individual therapeutic approaches in patients with brain metastases. Within the manuscript we are discussing benefits and limitations of our system but in the end it is a tiny step in bringing the personal medicine closer to the patients. Many thanks to all who participated in this work. "A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases" https://lnkd.in/eDNky9-G

Rapid Generation of GBOs for Real-Time Assessment in a Phase 1 Clinical Trial 💡 Trial Design: Parallel evaluation of treatments in both patients and patient-derived GBOs. 💊Therapeutic Insights: GBOs treated with patient-derived CAR-T cells exhibit cell cytolysis and reduction in target antigens. 📢Correlative Analysis: Cytokine release and cytolysis levels in GBOs align with patient clinical metrics, offering predictive insights.

We look forward to presenting preclinical research for our tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution. The findings presented in two posters demonstrate that ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in models of lung and kidney fibrosis. The posters will be available on the aTyr website once presented. For more information, read here: https://bit.ly/41jQwpI

Introducing KiNet: A New Web Portal Empowering Drug Discovery and Systems-Level Analysis of Critical Kinase-Substrate Interactions By integrating data from multiple public databases, KiNet enables the scientific community to visualize and study these interactions in systemwide contexts, enhancing the understanding of kinase functions and their implications in diseases like cancer, neurodegenerative disorders, and cardiovascular diseases. This portal is poised to advance research into complex cellular pathways and accelerate drug discovery efforts. 🔗 Learn More: https://lnkd.in/e5cYW9Ev 🔗 Explore KiNet: https://lnkd.in/eq7zC9py Gaurav Pandey, Avner Schlessinger #BiomedicalResearch #SystemsBiology #DrugDiscovery #Bioinformatics #PrecisionMedicine

📣🧪🧬Glad to share that our newst work about "TRPA1 Contributes to FGFR2c Signaling and to Its Oncogenic Outcomes in Pancreatic Ductal Adenocarcinoma-Derived Cell Lines" has been published in Cancers MDPI MDPI #FGFR2c #PDAC #TRPA1

💡 SABCS 2024 | Unveiling #mRNA Expression in #ADCTargets for #mBC 💡 Dr. Kristien Borremans shares insights from the #UPTIDERtrial (NCT04531696), exploring #mRNA expression in #metastaticbreastcancer (mBC) This study analyzed 72 ADC targets across #metastatic and normal tissues, shedding light on therapeutic precision for mBC treatment 🔦 Key findings: 🔍 High expression of #FN1, #MUC1, and #HER3 in #metastatic samples 🎯 Moderate expression of #HER2 and #TROP2, with inter- and intra-patient variability 🧬 Organ-specific expression and target correlations offer pathways for ADC optimization 🔗 Dive into the full discussion 👉 https://lnkd.in/eDQW4Pv4 #SABCS24 #BCSM #TrialUpdate #ImmunoOnc #CTSM #VJOncology #Oncologynews